---
id: anthrax_062
category: organisms
tags: [anthrax, bacillus-anthracis, bioterrorism, cutaneous, inhalational, ciprofloxacin, doxycycline]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Anthrax (Bacillus anthracis) - Bioterrorism Agent

**Q:** What are the clinical forms of anthrax, their presentations, and treatment strategies including bioterrorism scenarios?

**A:**

**Microbiology:**
- **Gram-positive rod** (large, box-car shaped)
- **Spore-forming** (spores can survive decades)
- **Capsule** (poly-D-glutamic acid) - antiphagocytic
- **Exotoxins:** Lethal toxin (LT), edema toxin (ET), protective antigen (PA)

**Epidemiology:**
- Zoonotic: Herbivores (cattle, sheep, goats)
- **CDC Category A bioterrorism agent** (high-priority threat)
- 2001 US anthrax letters: 22 cases (5 deaths)

---

**Clinical Forms:**

**1. Cutaneous Anthrax (95% of natural cases):**

**Transmission:** Direct contact with infected animals/products (hides, wool, bone)

**Clinical Presentation:**

**Timeline:**
- Day 1-2: **Painless pruritic papule** (insect bite-like)
- Day 2-3: **Vesicle** → ruptures → **painless black eschar** ("anthrax" = Greek for coal)
- Day 3-7: **Massive edema** (gelatinous, non-pitting) surrounding eschar
- **Painless** (key distinguishing feature)
- **Regional lymphadenopathy**

**Key Feature:** **Black eschar + painless edema** = pathognomonic

**Prognosis:**
- **Mortality <1% with treatment**, 5-20% untreated

**2. Inhalational Anthrax (Bioterrorism Scenario):**

**Transmission:** Inhalation of aerosolized spores

**Pathophysiology:**
- Spores phagocytosed by macrophages → transported to mediastinal lymph nodes
- Germination → toxin production → hemorrhagic mediastinitis, sepsis

**Clinical Presentation (Biphasic):**

**Phase 1: Prodrome (1-3 days):**
- Flu-like: Fever, myalgias, fatigue, non-productive cough
- **Chest discomfort** (NOT typical URI symptoms)

**Phase 2: Fulminant (24-48h later):**
- **Sudden deterioration**
- **Severe respiratory distress, dyspnea**
- **Hemorrhagic pleural effusions**
- **Shock, meningitis** (50%)
- **Widened mediastinum** on CXR (hemorrhagic mediastinitis)

**Key Imaging Finding:**
- **Widened mediastinum** (>8 cm at T8 level)
- **Pleural effusions** (hemorrhagic)
- **No pneumonic infiltrates** (NOT pneumonia!)

**Prognosis:**
- **Mortality ~45-90% even with treatment**
- Without treatment: nearly 100% fatal

**3. Gastrointestinal Anthrax (Rare):**

**Transmission:** Ingestion of contaminated meat

**Clinical Presentation:**
- **Oropharyngeal:** Mucosal ulcer → neck swelling, dysphagia
- **Intestinal:** Severe abdominal pain, bloody diarrhea, ascites
- **Mortality: 25-60%**

**4. Injection Anthrax (Emerging - Heroin Users):**

**Epidemiology:** Scotland, Germany (contaminated heroin)

**Clinical Presentation:**
- Severe soft tissue infection
- Differs from cutaneous (no eschar, very painful)
- High mortality (30-40%)

---

**Diagnosis:**

**Specimens:**
- **Blood cultures** (for systemic disease)
- **Vesicle fluid** (Gram stain, culture)
- **Pleural fluid** (inhalational)
- **Stool, ascites** (GI)

**Microbiology:**
- **Gram stain:** Large Gram-positive rods ("box-car" shaped)
- **Culture:** Medusa head colonies on blood agar
- **PCR:** Rapid detection

**Key Lab Findings (Inhalational):**
- **Widened mediastinum** on CXR/CT
- **Hemorrhagic pleural effusions**
- **Positive blood cultures** (if septic)
- **CSF:** Hemorrhagic if meningitis

---

**Treatment:**

**1. Cutaneous Anthrax (Uncomplicated):**

**Oral Antibiotics x 7-10 days:**

| **Antibiotic** | **Dosing** |
|----------------|------------|
| **Doxycycline** (preferred) | 100 mg PO BID |
| **Ciprofloxacin** | 500 mg PO BID |
| **Levofloxacin** | 500-750 mg PO daily |

**Key Points:**
- Do NOT incise/drain lesion (↑ dissemination)
- Treat all cutaneous anthrax (prevent progression to systemic)

**2. Inhalational Anthrax / Systemic / Bioterrorism:**

**Multidrug IV Regimen:**

**Backbone (Choose 1):**
- **Ciprofloxacin** 400 mg IV q8-12h OR
- **Levofloxacin** 750 mg IV q24h OR
- **Doxycycline** 100 mg IV q12h

**PLUS**

**Protein Synthesis Inhibitor (Choose 1):**
- **Linezolid** 600 mg IV q12h (preferred)
- **Clindamycin** 900 mg IV q8h
- **Rifampin** 600 mg IV/PO q12h

**PLUS (if CNS involvement suspected):**

**β-Lactam:**
- **Meropenem** 2g IV q8h (best CNS penetration)

**Rationale for Combination:**
- **Bactericidal synergy**
- Inhibit toxin production (protein synthesis inhibitors)
- Rapid killing (prevent toxin accumulation)

**Duration:**
- **≥60 days total** (IV x 2-3 weeks → switch to PO to complete 60 days)
- Spores can germinate weeks later (long treatment prevents relapse)

**Adjunctive Therapy:**
- **Anthrax antitoxin** (raxibacumab, obiltoxaximab) - monoclonal antibodies against PA
  - Available from CDC Strategic National Stockpile
  - Use for systemic anthrax

**3. Meningitis:**
- Triple therapy: Fluoroquinolone + linezolid + meropenem
- Corticosteroids considered
- **Mortality >90%** (even with treatment)

---

**Post-Exposure Prophylaxis (PEP) - Bioterrorism:**

**Indications:**
- Confirmed/suspected exposure to aerosolized B. anthracis spores

**Regimen:**

**Antibiotics x 60 days:**
- **Ciprofloxacin** 500 mg PO BID x 60 days OR
- **Doxycycline** 100 mg PO BID x 60 days

**PLUS**

**Anthrax Vaccine:**
- 3-dose series (0, 2, 4 weeks) during PEP
- Vaccines help immune system clear germinating spores

**Why 60 days?**
- Spores can remain dormant for weeks before germinating
- Antibiotics only kill vegetative forms (not spores)

---

**Comparison: Cutaneous vs Inhalational Anthrax**

| **Feature** | **Cutaneous** | **Inhalational** |
|-------------|---------------|------------------|
| **% of natural cases** | 95% | <5% |
| **Bioterrorism risk** | Low | ✅ High (Category A) |
| **Key finding** | **Painless black eschar** | **Widened mediastinum** |
| **Mortality (treated)** | <1% | 45-90% |
| **Treatment** | Oral monotherapy 7-10 days | **IV multidrug ≥60 days** |
| **Prodrome** | None | Flu-like → sudden deterioration |

---

**Mnemonic: "ANTHRAX = A Black Painful-less Eschar"**
- **A**erosolized spores (bioterrorism)
- **N**o pain (cutaneous lesion is painless)
- **T**oxins (lethal toxin, edema toxin)
- **H**emorrhagic mediastinitis (inhalational)
- **R**apid deterioration (fulminant phase)
- **A**ntibiotics x 60 days (PEP/systemic)
- **X** = widened mediastinum on X-ray

**Mnemonic: "Inhalational Anthrax = Widened Mediastinum, NOT Pneumonia"**
- Hemorrhagic **mediastinitis** (not pneumonia)
- **Widened mediastinum** on CXR
- Pleural effusions (hemorrhagic)
- **NO infiltrates**

**Clinical Pearls:**
- **Cutaneous anthrax: Painless black eschar** = pathognomonic
- **Inhalational anthrax: Widened mediastinum + hemorrhagic pleural effusions** (NOT pneumonia!)
- Think bioterrorism if **cluster of inhalational anthrax cases** (does NOT occur naturally)
- **Do NOT incise/drain cutaneous lesion** (bacteremia risk)
- **Multidrug therapy for systemic anthrax** (monotherapy insufficient)
- **60-day treatment for systemic/inhalational** (spores germinate for weeks)
- **PEP = 60 days antibiotics + 3-dose vaccine**
- Anthrax toxin-targeted monoclonal antibodies available (raxibacumab, obiltoxaximab) from SNS
- **Meningitis → triple therapy** (fluoroquinolone + linezolid + meropenem)
- Hemorrhagic meningitis has >90% mortality

**Media:** None

**Sources:** [CDC 2024 - Anthrax clinical treatment], [MedlinePlus 2024 - Anthrax], [Medscape 2024 - Anthrax treatment], [NCBI Bookshelf 2024 - Antibiotics for anthrax PEP], [PMC 2017 - Combination drug therapy], [Goldman-Cecil Medicine 2024]
